Abstract:Objective To evaluate the effects of the polymorphisms of CYP2C19,ABCB1 genes on the clopidogrel response and clinical vascular events in patients with acute ischemic stroke.Methods We recruited 209 acute ischemic stroke patients treated with clopidogrel from February 2012 to February 2014.The platelet inhibitive rate with clopidogrel treatment for 5 days was measured using thrombelastography.The CYP2C19*2/*3 and ABCB1 C3435T/T (-620) C genotypes were screened by the ligase detection reaction.The relationships between the gene polymorphisms and platelet inhibitive rate were analyzed with one-way analysis of variance and multivariate linear regression.The primary endpoint was the composite of vascular death,stroke recurrence and acute myocardial infarction.The associations between the genotype and primary endpoint were evaluated by the Kaplan-Meier method.The risk factors of the primary endpoint were analyzed by the Cox proportional hazards model.Results The platelet inhibitive rate in patients with homozygous (TT) of ABCB1 C3435T (42.9％ ± 14.2％) was significantly lower than that in patients with heterozygous (TC;53.2％ ± 21.3％) and wild-type genotypes (CC;58.1％ ± 21.2％;F =5.517,P =0.005).The platelet inhibitive rate in patients with CYP2C19 loss of function (LOF) alleles showed that the intermediate metabolized type (51.8％ ± 25.4％) and chronic metabolized type (44.5％ ± 22.6％) were lower than extensive metabolized type (59.3％ ± 23.2％;F =4.278,P =0.015).However,there was no statistically significant difference among the subtypes of ABCB1 T (-620) C.Multivariable linear regression model demonstrated that the CYP2C19* 2/* 3 and ABCB1 C3435T polymorphisms were independently associated with the platelet inhibitive rate.In addition,the higher body mass index (＞ 26 kg/m2) was significantly associated with lower platelet inhibitive rate.Kaplan-Meier analysis showed that the risks of primary endpoint increased in CYP2C19 LOF allele carrier during (9.5 ± 5.2) months follow-up (X2 =4.842,P =0.028).The CYP2C19 gene polymorphisms and age were independent risk factors for primary endpoint in the final multivariate Cox regression model.There was no significant relationship between the polymorphisms of ABCB1 gene and the primary endpoint.Conclusion For patients with acute ischemic stroke who carried CYP2C19 LOF alleles,the pestcide effect of clopidogrel was decreased and the risk of ischemic events was increased.

Association Between CYP2C19 and ABCB1 Polymorphisms and Clopidogrel Resistance in Clopidogrel-Treated Chinese Patients

Gene Polymorphisms of Insulin Secretion Signaling Pathway Associated with Clopidogrel Resistance in Han Chinese Population.

Effects of CYP2C19 variant alleles on postclopidogrel platelet reactivity and clinical outcomes in an actual clinical setting in China.

Effect of genetic and coexisting polymorphisms on platelet response to clopidogrel in Chinese Han patients with acute coronary syndrome

Influence of CYP2C19 loss-of-function variants on the antiplatelet effects and cardiovascular events in clopidogrel-treated Chinese patients undergoing percutaneous coronary intervention

The Association between ABCB1 Gene rs2235048 Single Nucleotide Polymorphism and Clopidogrel Resistance

Efffect of the ABCC3 –211C/T Polymorphism on Clopidogrel Responsiveness in Patients with Percutaneous Coronary Intervention

Association between cytochrome P450 3A4 gene 894C＞T single nucleotide polymorphism and clopidogrel resistance

CYP2C19*2 and Other Allelic Variants Affecting Platelet Response to Clopidogrel Tested by Thrombelastography in Patients with Acute Coronary Syndrome

Effect of CYP2C19 gene Polymorphism on Clopidogrel Resistance After PCI

CYP2C19 Polymorphisms and Antiplatelet Effects of Clopidogrel in Acute Ischemic Stroke in China

Effects of CYP2C19 and ABCB1 Gene Polymorphisms on Anti-Platelet Function of Clopidogrel and Recurrent Vascular Events in Patients with Acute Ischemic Stroke

CYP2C19 681G > A Polymorphism and Pharmacokinetics of Clopidogrel in Chinese Healthy Volunteers.

Effect of CYP2C19 polymorphism on platelet P2Y12 receptor signaling pathway in Chinese patients with stable coronary artery disease after the treatment of clopidogrel

Influence of genetic polymorphisms in P2Y12 receptor signaling pathway on antiplatelet response to clopidogrel in coronary heart disease

Association between CYP3A4 gene polymorphisms and clopidogrel response in patients with cardio-cerebrovascular diseases:a systematic review and Meta-analysis

The effects of CES 1 A 2 and CYP 2 C 19 polymorphisms on responsiveness to clopidogrel and clinical outcomes among Chinese patients with acute ischemic stroke

CYP2C19 Genotyping Combined with On-Clopidogrel Platelet Reactivity in Predicting Major Adverse Cardiovascular Events in Chinese Patients with Percutaneous Coronary Intervention.

CYP2C19 polymorphisms and coronary heart disease risk factors synergistically impact clopidogrel response variety after percutaneous coronary intervention

Clinical analysis of clopidogrel resistance in patients with coronary heart disease after percutaneous coronary intervention

Effect of CYP2C19 681G ＞ A and 636G ＞ A Polymorphisms on Residual Platelet Reactivity and Adverse Clinical Events in Clopidogrel-Treated Survivors after Percutaneous Coronary Intervention